VANCOUVER, British Columbia, Oct. 14, 2020 (GLOBE NEWSWIRE) — NeuroPharm, Inc. (“NeuroPharm”), a wholly-owned subsidiary of Mydecine Innovations Group Inc. (CSE:MYCO)(OTC:NLBIF)(FSE:0NF) (“Mydecine” or the “Company”) announced today it has engaged FreeMind Group LLC to assist NeuroPharm in securing non-dilutive funding opportunities globally.
NeuroPharm™ is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations including Veterans, emergency medical services personnel and other high-risk constituencies. In collaboration with its strategic partners, NeuroPharm is deploying evidence-based medicine in the establishment of psilocybin-based therapies addressing the unmet needs of high-risk constituents. ...
Read The Full Article On StreetSignals.com
Get the latest stock market news on StreetSignals . Follow public companies and get free stock research reports and stock market analysis data and stock tips.
All content provided by StreetSignals is subject to our Terms Of Use and Disclaimer .
For further details see:
Mydecine Innovations Group Subsidiary NeuroPharm Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities